Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
NervGen Pharma Corp
V.NGEN
Alternate Symbol(s):
NGENF
Healthcare
NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in discovery, development and commercialization of pharmaceutical products for the treatment of nervous system damage due to injury or disease. The Company is advancing its lead compound, NVG-291, for the treatment of spinal cord injury (SCI), Alzheimer’s disease (AD) and multiple sclerosis (MS). Its NVG-291 is a...
therapeutic peptide, which is a mimetic of the intracellular domain of protein tyrosine phosphatase, a cell surface receptor known to interact with chondroitin sulfate proteoglycans (CSPGs) and to be involved in the regulation of neuroplasticity and central nervous system repair. It has also initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury. The Company's wholly owned subsidiaries include NervGen US Inc. and NervGen Australia Pty Ltd.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
TSXV:NGEN - Post Discussion
NervGen Pharma Corp
> This has 1,000 bagger potential, article coming next week
New Post
View:
Discussion
List
(20)
•••
Geodan2
X
View Profile
View Bullboard History
Post by
Geodan2
on Apr 29, 2022 3:43pm
This has 1,000 bagger potential, article coming next week
NervGen Regenerates Neurons, What Is A Drug That Reverses Paralysis, MS, Stroke And Alzheimer's Worth? Apr. 23, 2022 7:17 PM ET| About: NervGen Pharma Corp. (NGENF), Includes: KRRGF, PTRUF Darp Research
Summary NervGen has already regenerated neurons under the microscope and in live rats with severed spinal cords. The rats regained most of the function in paralyzed legs.
The market cap of NervGen is under $80 million. It is currently in Phase 1 FDA trials in humans and is about to go into Phase 2.
NervGen has exclusive rights to the technology from Case Western University. It is backed by top experts in the field and staffed by very high level pharma executives. It has no competitors that can repair damage to the nervous system.
If it works 50% as well in humans as in animals, a $15 billion market cap is feasible. It is rare to find drug developer that has an outstanding risk/reward proposition. Most are bad investments that go bankrupt or lose much of their value from my observation. NervGen Phrama, (NGEN.TSX-V)(OTCPK:NGENF) is a big exception to the common overvaluation in this sector.
I have over 75 stocks in my portfolio and NervGen is the only drug company stock in it. The social good possible from their drug is the best have ever seen. Plus the investment potential of the company is also the best have ever seen.
Doing stock research is something I have spent about 25 hours a week doing for the last 20 years. By accident saw a video about them and their drug candidate. After watching the videos below and doing more research on the company, see it as the highest potential stock have ever found. Here is link to 2 videos in article. It is about 10 pages long, hopefully will be out early next week, awaiting one final proof. I am submitting as an article not a blogpost. That is on SeekingAlpha.
https://youtu.be/9paZgPPjn_c
+
Very informative interview with CEO A medical doctor was interviewed about NervGen and sees them the same as I do. It is Dr. Mark Swaim, founder of BioPub. He has made it the largest position in his portfolio and says it is the best drug stock investment he has ever seen. That video is below. It is queued to where he talks about NervGen.
https://youtu.be/F6WOF0Zprao?t=711
+
I have recently sold down to 10% on my Karora position with excellent multi-bagger profit. NervGen is a stock most of the profit has gone into. Talked with the CEO about an hour this week, like how he is running NervGen. Their team is stellar as you will see here:
https://nervgen.com/management/
click on the names and you will find it hard to believe the stock is only ay $80 million market cap.
Cheers
(0)
•••
WALLSTREEETHERO
X
View Profile
View Bullboard History
Comment by
WALLSTREEETHERO
on Jun 28, 2023 10:55am
https://finance.yahoo.com/news/nervgen-pharma-receive-more-us-123000753.html
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Discover Options Trading Strategies to Minimize your Tax Burden